Monograph Details
|
|
Ob/Gyn
> Menopause and HRT
|
|
ORTHO-EST |
| Manufacturer |
|
Women First HealthCare |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Estrogen. |
| Generic Name |
|
Ortho-Est .625 (estropipate 0.75mg), Ortho-Est 1.25 (estropipate 1.5mg); scored tabs. |
| Indications |
|
Moderate to severe vasomotor symptoms of menopause. Atrophic vaginitis. Kraurosis vulvae. Osteoporosis prevention. Hypoestrogenism. |
| Children |
|
Not applicable. |
| Adults |
|
Menopause, atrophic vaginitis: 0.75–6mg (as estropipate) daily, give cyclically (3 weeks on, 1 week off). Osteoporosis prevention: 0.75mg (as estropipate) daily, give cyclically (25 days of a 31-day cycle). Hypoestrogenism: 1.5mg–9mg (as estropipate) daily for 3 weeks, given cyclically (3 weeks on, 8–10 days off). See literature. Reevaluate periodically. |
| Contraindications |
|
Breast or estrogen-dependent carcinoma. Undiagnosed abnormal genital bleeding. Thromboembolic disorders. Thrombophlebitis. Pregnancy (Cat.X). |
| Precautions |
|
Patients with an intact uterus should almost always receive a progestin to avoid endometrial hyperplasia. Conditions aggravated by fluid retention. Hepatic dysfunction. Bone disease associated with hypercalcemia. Do initial complete physical and repeat annually (include BP, mammogram, and Pap smear). Discontinue if jaundice or hypertension occurs. Nursing mothers. |
| Adverse Reactions |
|
See literature. Increased risk of thromboembolic disorders, gallbladder disease. GI upset, breakthrough bleeding, edema, weight changes, mastodynia, hypertension, intolerance to contact lenses. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
